Conclusion
Through this observation, we come to two conclusions. Firstly, infection with SARS-CoV-2 could be a differential diagnosis of a PRES related to anticalcineurins. Nevertheless, it is essential to establish the correct diagnosis because management depends on it. Secondly, CSA would be a protective factor against infection by SARS-CoV-2 and its cessation would not be justified during infection by this virus.